Bristol-Myers Squibb UK has moved into a new state-of-the-art head office in Uxbridge.
The £5.5 million building houses over 200 employees, and BMS says the offices symbolise its commitment to working and investing in the UK.
David Veitch, European vice-president and general manager of Bristol-Myers Squibb UK, said: "Bristol-Myers Squibb is a pharmaceutical company that is looking confidently to the future; the modern, open and innovative design of our new head office reflects this confidence."
Meanwhile, Exelixis Inc. (EXEL) and BMS have agreed to jointly discover, develop and sell therapies against various cardiovascular and metabolic disorders.
The collaboration will focus on developing therapies against the liver x receptor, a nuclear hormone receptor implicated in a variety of disorders.
Exelixis has identified a series of proprietary drug candidates that it said are highly potent, selective and effective in animal models of atherosclerosis.
BMS will assume responsibility for clinical development, regulatory, manufacturing and sales activities for products of the collaboration.
Insider says: Way to go BMS. Are you planning to put the team that developed Pargluva onto this project?
http://pharmagossip.blogspot.com/2005/11/pargluva-illusion-of-safety.html
No comments:
Post a Comment